Aurora Cannabis Inc. (ACB:CA) (ACB)
Aurora Cannabis Inc. had its 12 month target price lowered at ATB Capital to $8.50 from $9.00, as the analyst adjusted its valuation assumptions to reflect persistent volatility in the cannabis sector and slower-than-expected market normalization in both Canada and Europe. Analysts emphasized that the reduced target is not a reflection of weakening fundamentals at Aurora specifically, but rather a recalibration tied to industry-wide pricing pressure, regulatory delays, and ongoing challenges in the recreational cannabis segment.
Despite trimming its price forecast, ATB reaffirmed its Outperform rating, signaling continued confidence in Aurora’s long-term positioning. Analysts highlighted several positive drivers supporting the rating. Aurora’s renewed focus on profitability, its progress in streamlining operations, and its leading presence in the global medical cannabis market, one of the few segments demonstrating stable demand growth. Additionally, Aurora’s emphasis on high-margin medical products and disciplined capital management has begun to strengthen its balance sheet and improve cash flow trends.
While acknowledging near-term headwinds, such as intense competition in the Canadian recreational market, price compression, and supply-chain inefficiencies, ATB believes Aurora has a clearer strategic path than many of its peers. The thesis is that if execution continues to improve international medical sales scale as expected, Aurora could outperform the broader cannabis sector over the next 12 to 24 months, even amid regulatory uncertainty.
STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.
